Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.

ABSTRACT: Clinical activity was observed in metastatic melanoma (MM) patients treated with ipilimumab (IPI) combined with fotemustine (FTM) in the phase II NIBIT-M1 study. Peripheral blood mononuclear cells (PBMCs) and serum were collected from MM patients at pre- and at weeks 12 and 24 post-treatment. A comprehensive phenotypic and functional immunomonitoring of circulating T cells, and the detection of soluble immunoregulatory molecules was carried out and correlated with clinical outcome. The frequency at baseline and along the treatment of circulating T central memory cells expressing activation/differentiation markers, such as CD3⁺CD4⁺CD45RO⁺BTLA⁺, CD3⁺CD4⁺4-1BB or Th17 lymphocytes correlated with the clinical outcome of MM patie

SUBMITTER: Maccalli C 

PROVIDER: S-EPMC4801454 | biostudies-literature | 2016 Feb

REPOSITORIES: biostudies-literature